De Hulan
De Hulan is the Vice President and General Manager of Eli Lilly China. He highlighted the importance of the recent changes in the drug approval landscape in China, stating that the country has become a key strategic market for multinational pharmaceutical companies, with innovative drugs being rapidly approved and integrated into medical insurance systems.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| China | 1 | 8.00 | 0.06% | +0% | 1,402,112,000 | 868,181 | $14,000,000 | 8,669$ |
| Totals | 1 | 1,402,112,000 | 868,181 | $14,000,000 | 8,669$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
China:
De Hulan emphasized the importance of China as a strategic market for multinational pharmaceutical companies.
8